慢性乙型肝炎患者幽门螺杆菌感染状况及肝组织螺杆菌属特异性16SrRNA基因分析*

doi:10.3969/j.issn.1672-5069.2016.01.008

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (1): 29-32.doi: 10.3969/j.issn.1672-5069.2016.01.008

慢性乙型肝炎患者幽门螺杆菌感染状况及肝组织螺杆菌属特异性16SrRNA基因分析*

王晓忠, 窦逾常, 王燕, 庄小芳

830000 乌鲁木齐市新疆维吾尔自治区中医医院肝病科（王晓忠,王燕,庄小芳）, 吉林大学中日联谊医院肝病科（窦逾常）

收稿日期:2015-04-28 出版日期:2016-01-10 发布日期:2016-02-04
通讯作者: 王燕,E-mail:wy751105@126.com
作者简介:王晓忠,男,45岁,医学硕士,主任医师。主要从事病毒性肝炎基础与临床研究。E-mail:wxz125@sina.com
基金资助:
*基金项目：新疆维吾尔自治区自然科学基金项目（编号: 2012211A096）

Helicobacter pylori infection status in Uygur patients with chronic hepatitis B and specificity 16SrRNA of helicobacter pylori in liver tissues

Wang Xiaozhong, Dou Yuchang, Wang Yan, Zhuang Xiaofang

Department of Hepatology,Traditional Chinese Medicine Hospital,XinJiang Uygur Autonomous Region,Urumqi 830000,Xinjiang Uygur Autonomous Region,China

Received:2015-04-28 Online:2016-01-10 Published:2016-02-04

摘要/Abstract

摘要： 目的分析慢性乙型肝炎患者幽门螺杆菌（Hp）感染状况及肝组织螺杆菌属特异性16SrRNA基因特点。方法纳入维吾尔族CHB患者60例和健康维吾尔族体检者80例,采用¹⁴C-尿素呼气试验检测H pylori阳性感染,常规进行肝穿刺,采用PCR法检测肝组织螺杆菌16SrRNA基因水平。结果慢性乙型肝炎每分钟衰变数（¹⁴C-UBT）阳性率为85.00%,显著高于对照组[60.24%,P<0.01];在所谓的60例慢性乙型肝炎患者中,经肝组织学检查,发现慢性乙型肝炎46例,肝硬化14例;在46例CHB和14例肝硬化患者肝组织DNA进行16 SrRNA基因检测,结果40例（86.96%）CHB和13例（92.86%）肝硬化患者16 sRNA阳性,两组差异无统计学意义（x²=0.363,P>0.05）;轻度、中度与重度CHB患者肝组织16 sRNA检出率亦无统计学差异（x²=1.348,P=0.510）。结论慢性乙型肝炎患者幽门螺杆菌感染率较高,但肝组织螺杆菌属特异性16SrRNA检出率与乙型肝炎患者肝组织炎症或纤维化程度未显示出显著性关联。

关键词: 慢性乙型肝炎, 幽门螺杆菌, 肝组织, 螺杆菌属特异性16SrRNA

Abstract: Objective To analyze the Helicobacter pylori（Hp） infection status in Uygur patients with chronic hepatitis B in Xinjiang and helicobacter 16SrRNA gene in liver biopsy tissues. Methods 60 patients with hepatitis B and 80 healthy persons were recruited in this study. ¹⁴C-urea breathing test was used to detected Hp infection,and helicobacter 16SrRNA gene in liver biopsy tissues were detected by using real-time PCR and pathological examination was applied to determine histological activity index. Results The ¹⁴C-UBT positive rate was 85.00% in patients with hepatitis B,significantly higher than 60.24% in the controls （P<0.01）; 14 out of 60 patients with hepatitis B were diagnosed with liver cirrhosis by histopathological examination; the positive rate of helicobacter 16SrRNA in liver tissues from patients with CHB were 86.96%,without significant difference as compared to 92.86% from patients with liver cirrhosis（x²=0.363,P>0.05）;there were no significantly statistical differences as respect to the positive rates of helicobacter 16SrRNA in liver tissues among 21,16 and 9 patients with hepatitis B of mild,moderate and severe degree（x²=1.348,P=0.510）. Conclusion The infection of Hp in patients with CHB is common,but there is no significant evidence showing correlation of the specificity 16SrRNA of Hp to pathological grading and staging in liver tissues.

Key words: Chronic hepatitis B, Helicobacter pylori, 16SrRNA of Hp, Liver biopsy

王晓忠, 窦逾常, 王燕, 庄小芳. 慢性乙型肝炎患者幽门螺杆菌感染状况及肝组织螺杆菌属特异性16SrRNA基因分析*[J]. 实用肝脏病杂志, 2016, 19(1): 29-32.

Wang Xiaozhong, Dou Yuchang, Wang Yan, Zhuang Xiaofang. Helicobacter pylori infection status in Uygur patients with chronic hepatitis B and specificity 16SrRNA of helicobacter pylori in liver tissues[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 29-32.

参考文献

[1] 中华医学会肝病学分会和中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）:81-89.
[2] Liang XF,Bi SL,Longd WZ,et al. Epidemiological serosurvey of hepatitis B in China:Declining HBV prevalence due to hepatitis B vaccination.Vaccine,2009,27（47）:6550-6557.
[3] Liang XF,Bi SL,Yang WH.et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis,2009,200（1）:39-47.
[4] Pon Zetto A,Pellieano R,Leone N,et al. Helicobaeter pylorieropreva-lance in cirrhotic patients with hepatitis B virus infection. Neth J Med,2000,56（6）:206-210.
[5] EI-masry S,EI-Shahat M,Badra G. Helicobacter pylori and hepatitis C virus coinfection in Egyptian patients. J Glob Infect Dis,2010,1（2）:914-923.
[6] Baldari CT,Lanzavecchia A,Telford JL. Immune subversion by Helicobacter pylori. Trends Immunol,2005,26（4）:199-207.
[7] 邓庆文,罗亮. 根除幽门螺杆菌对不同程度慢性乙型病毒性肝炎患者的影响. 中国医师杂志,2009,11（10）:1424-1428.
[8] 卢琳琳,胡东胜,刘冬娜. 肝硬化HP感染者血清细胞因子和内毒素水平测定的临床意义. 实用肝脏病杂志,2009,12（3）:218-219.
[9] 杜建新,蒋锦,华芦红. 门脉高压性胃病患者幽门螺杆菌感染率调查. 实用肝脏病杂志,2012,15（1）:32-33.
[10] 王甦,李翠,陈凤娟,等. 乙肝相关性肝病患者幽门螺杆菌感染的研究. 实用临床医药杂志,2013,11（3）:39-42.
[11] 季尚玮,王江滨,张永贵.慢性乙型肝炎患者肝组织中螺杆菌菌属特异性1 6SrRNA基因及Hp特异性基因分析. 肝脏,2009,14（6）:449-452.
[12] 库热西江·托呼提,哈木拉提·吾甫尔,张利占,等. 和田地区维吾尔族、汉族人群HBsAg携带率的流行病学调查分析. 第一军医大学学报,2004,24（11）:1287-1288.
[13] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南. 中华肝脏病杂志,2006,14（11）:866-870.
[14] 陈文彬,潘祥林,康熙雄. 诊断学. 北京:人民卫生出版社,2004:389．
[15] 彭文伟,李兰娟,乔兴彦.传染病学. 北京:人民卫生出版社,2003:33.
[16] Fox JG,Dewhirst FE,Tully JG,et al. Helicobacter hepaticus sp. nov,a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol,1994,32:1238-1245.
[17] Chen SJ,Wang IJ,Zhu Q,et a1. Effect of Hpylori infect and its eradication on hyperammonemia and hepatic encephalopathy in cirrhotic patients. World J Gastroenterol,2008,14（12）:1914-1918.
[18] Nilsson HO,Taneera J,Castedal M,et al. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization,and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliarycirrhosis. J Clin Microbiol,2000,38（3）:1072-1076.
[19] Rocha M,Avenaud P,Menard A,et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut,2005,54:396-401.
[20] 艾斯凯尔﹒ 阿斯木,麦麦提﹒ 图尔荪,麦麦提﹒ 买地尼也提,等.新疆维、汉、哈族有消化道症状患者幽门螺旋杆菌感染率分布特征与高危因素及相关疾病的分析.新疆医学,2012,42（1）:4-9.
[21] 柯柳,温小凤,蒋忠胜,等. 幽门螺杆菌感染与慢性乙型肝炎患者肝脏炎症及纤维化的关系.山东医药,2012,52（13）:52-54.
[22] 庞念德,陈安海. 乙型肝炎病毒及幽门螺杆菌感染对慢性乙型肝炎患者胃粘膜病变的影响. 河北医学,2014,20（12）:1964-1968.
[23] Ge Z,Rogers AB,Feng Y,et al. Bacterial cytolethal distending toxin pro -motes the development of dysplasis in a model of microbially indeced hepatocarcinogenesis. Cell Microbiol,2007,9（8）:2070-2080.

慢性乙型肝炎患者幽门螺杆菌感染状况及肝组织螺杆菌属特异性16SrRNA基因分析*

Helicobacter pylori infection status in Uygur patients with chronic hepatitis B and specificity 16SrRNA of helicobacter pylori in liver tissues

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.